论文部分内容阅读
观察了靶向 C- raf m RNA ( ISIS51 32 )和PKC- α m RNA( ISIS352 1 )的反义硫代寡核苷酸合用对肺腺癌 A549细胞体外增殖的抑制作用 ( MTT法 ) .单用药组药物浓度为 50 0 ,2 0 0和 80 nmol·L-1;合用组 A两药浓度分别为 2 50 ,1 0 0及 40 nmol· L-1,即两药药量减半 ,药物摩尔浓度之和与单用药相同 .合用组 B两药浓度分别为 50 0 ,2 0 0及 80nmol·L-1,但作用时间减半 (各 3h) ,两药作用时间之和与单用药相同 .结果表明 ,在合用组 A,两药浓度水平为 1 0 0 nmol· L-1时 ,对 A549细胞生长的抑制作用大于 ISIS352 1单用药组的 2 0 0 nmol· L-1水平 ( P<0 .0 1 ) ;在合用组 B,两药浓度水平为 2 0 0和 80 nmol· L-1时 ,对 A549细胞生长的抑制作用分别大于 ISIS352 1单用药组的 2 0 0 nmol· L-1和ISIS51 32单用药组的 80 nmol· L-1水平 ( P<0 .0 1 ) ;其余合用组各个药物浓度水平的效应 ,与相应的单用药组的效应相近 .提示靶向不同癌基因的反义药物合用 ,可能增强对肿瘤细胞的抑制作用 .
Inhibition of proliferation of human lung adenocarcinoma A549 cells (MTT assay) in vitro by antisense oligonucleotides targeting C-raf m RNA (ISIS 51 32) and PKC-α m RNA (ISIS352 1) was observed. The drug concentration in the treatment group was 50 0, 200 and 80 nmol·L-1, respectively. The concentrations of the two drugs in combination group A were 50, 100 and 40 nmol · L-1, respectively, The molar concentration and the same single drug combination group B two drug concentrations were 50 0, 200 and 80nmol·L-1, but the role of half-time (3h), the two drugs with the same time and the same medication The results showed that in combination group A, the inhibitory effect on the growth of A549 cells was stronger than that of ISIS352 1 group at the concentration of 100 nmol·L-1 (200 nmol · L-1, P < 0. 01). In combination group B, the inhibitory effects on the growth of A549 cells at two drug concentrations of 200 and 80 nmol · L-1 were respectively greater than those of ISIS352 1-treated group at 200 nmol · L- 1 and ISIS51 32 single-drug group (P <0.01). The effect of each drug concentration in the other combined groups was similar to that of the corresponding single-drug group, suggesting that targeting different oncogenes of Antisense drugs, may enhance the inhibition of tumor cells.